Zusammenfassung

• Objekte (1 geändert, 0 hinzugefügt, 0 gelöscht)
  • Wikiderm.EntryClass[0]

Details

Wikiderm.EntryClass[0]

Eintrag

...	...	@@ -59,11 +59,17 @@
59	59	(% class="Bullet" %)-(%%) Pyoderma gangraenosum
60	60
61	61	(% class="Eintrag-2" %)
62		-(% class="Feature" %)TF:(%%) Infekte
	62	+(% class="Feature" %)TF:(%%) (% class="Bullet" %)-(%%) Infekte
63	63
64	64	(% class="Ebene-2" %)
65	65	(% class="Feature" %)Bsp:(%%) Mycoplasma pneumoniae, HIV
66	66
	67	+(% class="Ebene-1" %)
	68	+(% class="Bullet" %)-(%%) Dupilumab
	69	+
	70	+(% class="Ebene-2" %)
	71	+(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2023 Nov 27. [[http:~~/~~/doi.org/10.1111/ajd.14190>>url:http://doi.org/10.1111/ajd.14190]]
	72	+
67	67	(% class="Eintrag-2" %)
68	68	(% class="Feature" %)DD:(%%) (% class="Bullet" %)-(%%) (% class="Abbreviation" %)AGEP(%%)
69	69
...	...	@@ -79,11 +79,14 @@
79	79	(% class="Ebene-1" %)
80	80	(% class="Bullet" %)-(%%) Pemphigus foliaceus
81	81
82		-(% class="Eintrag-2" %)
	88	+(% class="Ebene-1" %)
	89	+(% class="Bullet" %)-(%%) anuläre Psoriasis pustulosa
83	83
	91	+(% class="Ebene-2" %)
	92	+(% class="Feature" %)Bsp:(%%) annular pustular psoriasis
84	84
85		-(% class="Ebene-1" %)
86		-(% class="Bullet" %)-(%%) Psoriasis pustulosa
	94	+(% class="Ebene-2" %)
	95	+(% class="Feature" %)Lit:(%%) Pediatr Dermatol. 2023 Jan 31. [[http:~~/~~/doi.org/10.1111/pde.15251>>url:http://doi.org/10.1111/pde.15251]]
87	87
88	88	(% class="Ebene-1" %)
89	89	(% class="Bullet" %)-(%%) Tinea incognito
...	...	@@ -188,8 +188,11 @@
188	188	(% class="Bullet" %)-(%%) Apremilast
189	189
190	190	(% class="Ebene-3" %)
191		-(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
	200	+(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
192	192
	202	+(% class="Ebene-3" %)
	203	+(% class="Bullet" %)-(%%) Australas J Dermatol. 2023 Aug;64(3):e310-e312. [[http:~~/~~/doi.org/10.1111/ajd.14073>>url:http://doi.org/10.1111/ajd.14073]]
	204	+
193	193	(% class="Ebene-2" %)
194	194	(% class="Bullet" %)-(%%) Anti-TNF-alpha
195	195
...	...	@@ -197,16 +197,8 @@
197	197	(% class="Feature" %)Stoff:(%%) (% class="Bullet" %)-(%%) **[[Infliximab]]**
198	198
199	199	(% class="Ebene-4" %)
200		-{{pharMacro style="Ebene-4"}}
201		-(% class="Feature" %)Phar:(%%) Remicade^^®^^
202		-{{/pharMacro}}
	212	+(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4, Dermatol Ther. 2022 May 4:e15552. [[http:~~/~~/doi.org/10.1111/dth.15552>>url:http://doi.org/10.1111/dth.15552]]
203	203
204		-(% class="Ebene-4" %)
205		-(% class="Feature" %)Dos:(%%) 5 mg/kg i.v.
206		-
207		-(% class="Ebene-4" %)
208		-(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4
209		-
210	210	(% class="Ebene-3" %)
211	211	(% class="Bullet" %)-(%%) Adalimumab
212	212